# Riddhi Siddhi Gluco Biols share price today (Riddhi Siddhi Gluco Biols Ltd, BSE: 524480)

> Riddhi Siddhi Gluco Biols share price today: ₹665.05 at the BSE close on 3 November 2026, up 22.3% in a year. Riddhi Siddhi Gluco Biols (BSE: 524480) is worth ₹474 crore, trades at a P/E of 33.5 and has closed between ₹411.20 and ₹823.45 over the past 52 weeks. > Riddhi Siddhi Gluco Biols Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. 524480 · Trading · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/riddhi-siddhi-gluco-biols-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Business trend: Turning around, from fewer quarters than usual
- Price: ₹665.05 (+22.3% in a year)
- P/E: 33.5× (higher than 97% of the last 10 years)
- Revenue (Jun 2026): ₹89.9 Cr (−41.9% on a year ago)
- Profit (Jun 2026): ₹3.0 Cr (−62.6% on a year ago)
- Operating margin: −3.0% (−2.8 points on a year ago)
- ROCE: 3%, FY26
- ROIC: −0.9%, against a 12.0% cost of capital: −12.9 points

The main question: foreign institutions moved +2.7 percentage points over 8 quarters while the business went the other way. ## What is the Riddhi Siddhi Gluco Biols share price today? Riddhi Siddhi Gluco Biols Ltd's share price was ₹665.05 at the close on 3 November 2026. It has been rising for 25 weeks. That is 1.0% below its average price over the last 200 trading days. Over the past 13 weeks it has done worse than the NIFTY 500, and it has been behind for 1 week running. In the last 52 weeks it traded between ₹411 and ₹823, and at that close it sat 62% of the way up from that low. Over the last 11 years the share price moved +120% while the NIFTY 500 moved +231%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 30 October 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Riddhi Siddhi Gluco Biols this quarter? One change stood out: revenue down on a year earlier for 4 quarters in a row. 1. Revenue down on a year earlier for 4 quarters in a row In the June 2026 quarter revenue was ₹90 crore, -41.9% on a year earlier. ## What are Riddhi Siddhi Gluco Biols' latest quarterly results? For April to June 2026 (the quarter ended 30 June 2026), Riddhi Siddhi Gluco Biols reported revenue of ₹89.9 crore, down 41.9% from ₹155 crore a year earlier, and a profit of ₹3.01 crore, down 62.6% from ₹8.04 crore. ### Riddhi Siddhi Gluco Biols results: April to June 2026 against a year earlier

| Measure | April to June 2026 | April to June 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹89.9 crore | ₹155 crore | −41.9% |
| Profit | ₹3.01 crore | ₹8.04 crore | −62.6% |
| Earnings per share | ₹4.29 | ₹11.05 | −61.2% |
| Operating margin | −3.0% | −0.2% | −2.8 points |

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). (From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.)

## What is the Riddhi Siddhi Gluco Biols share price history? Riddhi Siddhi Gluco Biols closed at ₹665.05 on 3 November 2026, up 22.3% from ₹544.00 a year earlier (31 October 2025) and up 88.2% over five years. Its highest weekly close since May 2016 was ₹840.30 on 23 February 2018. ### Riddhi Siddhi Gluco Biols share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹640.35 | +3.9% |
| 1 month ago · 1 Oct 2026 | ₹710.90 | −6.4% |
| 6 months ago · 30 Apr 2026 | ₹623.95 | +6.6% |
| 1 year ago · 31 Oct 2025 | ₹544.00 | +22.3% |
| 3 years ago · 3 Nov 2023 | ₹384.70 | +72.9% |
| 5 years ago · 4 Nov 2021 | ₹353.40 | +88.2% |
| 10 years ago · 4 Nov 2016 | ₹356.70 | +86.4% |
| Earliest weekly close in our records · 13 May 2016 | ₹302.00 | +120.2% |
| Highest weekly close since May 2016 · 23 Feb 2018 | ₹840.30 | −20.9% |
| Lowest weekly close since May 2016 · 27 Mar 2020 | ₹188.30 | +253.2% |
| 52-week high (weekly close) · 19 Jun 2026 | ₹823.45 | −19.2% |
| 52-week low (weekly close) · 27 Mar 2026 | ₹411.20 | +61.7% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (554 weekly closes from 13 May 2016 to 3 November 2026.)

## What is the latest news on Riddhi Siddhi Gluco Biols? 3 Nov 2026: Riddhi Siddhi Gluco Biols closed at ₹665.05, up 3.9% on the week and down 6.4% on the month. Results for April to June 2026: Revenue down 41.9% and profit down 62.6% on a year earlier. ## What dividend does Riddhi Siddhi Gluco Biols pay? Not in its latest year. Riddhi Siddhi Gluco Biols Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 4 of its last 11 reported years, so there is a history but no current dividend (as of 3 November 2026). ## Which stock lists is Riddhi Siddhi Gluco Biols on? Riddhi Siddhi Gluco Biols is not on any of our India lists this week. ## Is Riddhi Siddhi Gluco Biols profitable? Riddhi Siddhi Gluco Biols Ltd earned ₹3.0 Cr of net profit in the Jun 2026 quarter, −62.6% on the same quarter a year earlier. The full FY26 year was a loss of ₹12.0 Cr. That is 3.3% of the quarter's revenue. The same quarter a year earlier earned ₹8.0 Cr. 3 of the last 12 reported quarters were loss-making. Why profit moved: revenue changed −41.9% on a year earlier and the margin moved −2.8 percentage points. Sales did the work while the margin got thinner. On average over the last four quarters, profit changed −288.9% and revenue −38.4%. Profit is growing slower than sales: rising costs are taking part of the growth. ## How much revenue does Riddhi Siddhi Gluco Biols make, and is it growing? Riddhi Siddhi Gluco Biols Ltd reported ₹89.9 Cr of revenue in the Jun 2026 quarter, −41.9% on the same quarter a year earlier. Over 10 years it has grown −3.6% a year on average. The last full year, FY26, came in at ₹236 Cr. The last four reported quarters add to ₹171 Cr. FY26 revenue was ₹236 Cr, +73.5% on the year before. Recent pace: the last four quarters grew −38.4% on average, against −3.6% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −38.0%, against −11.5% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does Riddhi Siddhi Gluco Biols keep? Riddhi Siddhi Gluco Biols Ltd's operating margin was −3.0% in the Jun 2026 quarter, 2.8 percentage points lower than the same quarter a year ago. Across 11 years it has been between −9.0% and 13.0%. The latest quarter is within that range. Why the margin moved: operating margin changed −2.8 percentage points on the year while gross margin changed +1.4 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Riddhi Siddhi Gluco Biols' profit turning into cash? Over the last 3 years, 409% of Riddhi Siddhi Gluco Biols Ltd's reported profit came in as cash from its operations, so the profit is backed by cash. In FY26 its operations used ₹9.0 Cr of cash, against −₹12.0 Cr of profit. After ₹0.0 Cr of spending on assets, free cash was −₹9.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 409% of profit came in as cash: the cash cycle got 145 days shorter between FY21 and FY26, so cash that used to wait in the business now arrives sooner. What to look at next: the bigger use of cash is spending on new assets, at 2.2× depreciation over three years. The next section checks what that spending is building. ## Where does Riddhi Siddhi Gluco Biols' cash go? Riddhi Siddhi Gluco Biols Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 66 days in FY26, down from 211 days in FY21. It spent ₹62.0 Cr on assets over the last 3 years. Customers take 13 days to pay, and stock sits for 79 days on average. At FY26 sales of ₹236 Cr, each day of that cycle ties up about ₹0.6 Cr, so roughly ₹43.0 Cr is tied up in the business at any time. FY26: customers took 13 days to pay and stock sat for 79 days, about 2.6 months of sales sitting as stock, for a full cycle of 66 days, shorter than FY21's 211. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 79 days. Customers pay about 13 days after that. Suppliers are paid at 26 days. Together that makes the 66-day cycle. Spending on assets: ₹62.0 Cr over the last 3 years, against ₹28.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Riddhi Siddhi Gluco Biols' P/E ratio, and how does it compare with its own history? Riddhi Siddhi Gluco Biols Ltd's P/E is 33.5×, near the high end of its own history: higher than 97% of past readings. Its usual P/E (the middle reading) is 8.5×, over 10 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 10 years the price moved +6.4% a year; about −9.8% a year came from earnings growth and about +16.2 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Riddhi Siddhi Gluco Biols business getting better or worse? Riddhi Siddhi Gluco Biols Ltd's business is turning around. Profit growth has swung from −81.3% at its low to −62.6%, rising from a low 1 quarters ago (from single-quarter figures), with ROCE steady at 3.0%. This is based on 9 quarters of 3 measures, with some gaps. Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution. ## How much does Riddhi Siddhi Gluco Biols earn on its capital? Riddhi Siddhi Gluco Biols Ltd earned a ROCE of 3% in FY26. That is up from a low of 0% in FY21. Its return on capital used (ROIC) is 12.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −5.1% net margin and 0.12× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −5.1% net margin × 0.12× asset turnover × 1.25× leverage (assets divided by equity) ≈ −0.8% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −0.9% − 12.0% = −12.9 percentage points. The 12.0% is a standard assumption for the cost of capital in India, not an estimate for this company. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Riddhi Siddhi Gluco Biols have too much debt? Riddhi Siddhi Gluco Biols Ltd had ₹283 Cr of borrowings against ₹1,509 Cr of equity in FY26, so its debt is 0.19× its equity. Its operating profit is −1 times its interest bill. Over 5 years borrowings went from ₹229 Cr to ₹283 Cr. Over the last 3 of those years it spent ₹62.0 Cr on assets. Part of the spending on assets is being paid for with borrowed money. ## What is the Riddhi Siddhi Gluco Biols shareholding pattern? Foreign institutions raised their stake in Riddhi Siddhi Gluco Biols Ltd by 2.7 percentage points over 8 quarters, the biggest change among its owners. Foreign institutions now own 2.7% of the company. Promoters moved +0.5 points over the same period, to 75.0%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Foreign institutions: +2.7 points over 8 quarters, to 2.7%; Promoters: +0.5 points over 8 quarters, to 75.0%; Domestic institutions: +0.0 points over 8 quarters, to 0.0%. Why the owners changed: foreign institutions drove it (+2.7 points), together with promoters (+0.5 points). They raised their stake step by step. ## How far is Riddhi Siddhi Gluco Biols from balance-sheet trouble? For Riddhi Siddhi Gluco Biols Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Riddhi Siddhi Gluco Biols rank in its industry? 38.9 out of 100, rank 31 of 63 in Trading, with 83% of the evidence available. Riddhi Siddhi Gluco Biols Ltd scores 38.9 out of 100 against the 63 companies it is compared with in Trading, ranking 31. Relative strength against the index is 17%, and revenue and profit growth are weak. The four parts add up to the total exactly: 13.1 + 6.4 + 6.3 + 13.1 = 38.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Riddhi Siddhi Gluco Biols compared with? Riddhi Siddhi Gluco Biols ranks 31 of 63 Trading companies on the 4-Factor Sector Score, with 38.9 out of 100. 1. [Mangalam Global Enterprise Ltd](https://www.sectoralpha.in/stocks/mangalam-global-enterprise-ltd) MGEL · turning · Most evidence points up · 93% evidence 70.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.5/35 · Revenue 44.2% · Profit 8.2% · Operating margin change 0.7 points · 100% evidence Capital efficiency 14.6/25 · ROCE 17% · Operating margin 2.3% · 100% evidence Valuation 15.8/20 · P/E 14.6× · PEG 0.31 · 65% evidence Relative strength 17.2/20 · Lead over its industry 12.9% · Lead over NIFTY 500 25.7% · 1 year 18.7% · 100% evidence · 5 of 12 weeks ahead Exact sum: 22.5 + 14.6 + 15.8 + 17.2 = 70.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Shankara Buildpro Ltd](https://www.sectoralpha.in/stocks/shankara-buildpro-ltd) BUILDPRO · quiet · Too little evidence to rank firmly · 59% evidence 64.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.0/43.75 · Revenue 26.3% · Profit 41.9% · Operating margin change -0.2 points · 88% evidence Capital efficiency 21.5/31.25 · ROCE 39% · Operating margin 3.2% · 100% evidence Valuation 13.4/25 · P/E 16× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 30 + 21.5 + 13.4 = 64.9 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 3. [Ivalue Infosolutions Ltd](https://www.sectoralpha.in/stocks/ivalue-infosolutions-ltd) IVALUE · quiet · Evidence leans up · 74% evidence 64.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 5.4% · Profit 22.1% · Operating margin change 5.6 points · 88% evidence Capital efficiency 19.8/25 · ROCE 25.4% · Operating margin 10% · 100% evidence Valuation 15.7/20 · P/E 10× · PEG 0.43 · 65% evidence Relative strength 8.1/20 · Lead over its industry n/a · Lead over NIFTY 500 -18.6% · 1 year -31.1% · 25% evidence · 3 of 12 weeks ahead Exact sum: 20.7 + 19.8 + 15.7 + 8.1 = 64.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Maxgrow India Ltd](https://www.sectoralpha.in/stocks/maxgrow-india-ltd) Too little evidence to rank firmly · 53% evidence 64.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.9/35 · Revenue 100% · Profit 100% · Operating margin change 0.8 points · 62% evidence Capital efficiency 16.4/25 · ROCE 23.5% · Operating margin 2.7% · 95% evidence Valuation 11.5/20 · P/E 1.2× · PEG n/a · 15% evidence Relative strength 12.4/20 · Lead over its industry n/a · Lead over NIFTY 500 136% · 1 year n/a · 25% evidence Exact sum: 23.9 + 16.4 + 11.5 + 12.4 = 64.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 5. [Nupur Recyclers Ltd](https://www.sectoralpha.in/stocks/nupur-recyclers-ltd) NRL · leader · Evidence leans up · 78% evidence 63.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 40.6% · Profit 29.8% · Operating margin change 3.6 points · 83% evidence Capital efficiency 15.3/25 · ROCE 15.1% · Operating margin 11.6% · 76% evidence Valuation 7.6/20 · P/E 64.4× · PEG n/a · 50% evidence Relative strength 19.9/20 · Lead over its industry 86.1% · Lead over NIFTY 500 100.5% · 1 year 134.9% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21 + 15.3 + 7.6 + 19.9 = 63.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Arisinfra Solutions Ltd](https://www.sectoralpha.in/stocks/arisinfra-solutions-ltd) ARIS · breaking out · Too little evidence to rank firmly · 56% evidence 61.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.5/35 · Revenue 45.3% · Profit 100% · Operating margin change 2 points · 83% evidence Capital efficiency 13.5/25 · ROCE 15.6% · Operating margin 11% · 76% evidence Valuation 10.7/20 · P/E 17.2× · PEG n/a · 15% evidence Relative strength 10.9/20 · Lead over its industry n/a · Lead over NIFTY 500 16.6% · 1 year -14.9% · 25% evidence · 11 of 12 weeks ahead Exact sum: 26.5 + 13.5 + 10.7 + 10.9 = 61.6 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 7. [Bhatia Communications & Retail (India) Ltd](https://www.sectoralpha.in/stocks/bhatia-communications-retail-indialtd) Evidence leans up · 68% evidence 60.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.7/35 · Revenue 49% · Profit 45.5% · Operating margin change 0.3 points · 83% evidence Capital efficiency 18.4/25 · ROCE 21.3% · Operating margin 5.3% · 95% evidence Valuation 9.2/20 · P/E 22.8× · PEG n/a · 50% evidence Relative strength 11.5/20 · Lead over its industry n/a · Lead over NIFTY 500 30.1% · 1 year n/a · 25% evidence Exact sum: 21.7 + 18.4 + 9.2 + 11.5 = 60.8 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 8. [DC Infotech & Communication Ltd](https://www.sectoralpha.in/stocks/dc-infotech-communication-ltd) DCI · breaking out · Evidence leans up · 81% evidence 60.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.3/35 · Revenue 29.1% · Profit 41.9% · Operating margin change 0.4 points · 88% evidence Capital efficiency 16.5/25 · ROCE 23% · Operating margin 4.8% · 100% evidence Valuation 13.4/20 · P/E 24.6× · PEG 0.82 · 100% evidence Relative strength 11.1/20 · Lead over its industry n/a · Lead over NIFTY 500 20.1% · 1 year n/a · 25% evidence · 6 of 6 weeks ahead Exact sum: 19.3 + 16.5 + 13.4 + 11.1 = 60.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [SG Mart Ltd](https://www.sectoralpha.in/stocks/sg-mart-ltd) SGMART · leader · Evidence leans up · 93% evidence 60.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.3/35 · Revenue 9.7% · Profit 26.7% · Operating margin change 3 points · 100% evidence Capital efficiency 11.6/25 · ROCE 10.2% · Operating margin 4.6% · 100% evidence Valuation 7.9/20 · P/E 71.1× · PEG 1.81 · 65% evidence Relative strength 18.3/20 · Lead over its industry 47.1% · Lead over NIFTY 500 60.5% · 1 year 146.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 22.3 + 11.6 + 7.9 + 18.3 = 60.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Tembo Global Industries Ltd](https://www.sectoralpha.in/stocks/tembo-global-industries-ltd) TEMBO · losing its lead · Evidence leans up · 71% evidence 59.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.6/35 · Revenue 34% · Profit 55.7% · Operating margin change 5 points · 83% evidence Capital efficiency 19.6/25 · ROCE 22.8% · Operating margin 16% · 76% evidence Valuation 11.2/20 · P/E 9.3× · PEG n/a · 15% evidence Relative strength 7.0/20 · Lead over its industry -19.2% · Lead over NIFTY 500 -8.7% · 1 year -20.8% · 100% evidence · 3 of 12 weeks ahead Exact sum: 21.6 + 19.6 + 11.2 + 7 = 59.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. [Rashi Peripherals Ltd](https://www.sectoralpha.in/stocks/rashi-peripherals-ltd) RPTECH · losing its lead · Evidence leans up · 78% evidence 59.3 out of 100 Growth Capital Valuation Relative
12. [Sudarshan Pharma Industries Ltd](https://www.sectoralpha.in/stocks/sudarshan-pharma-industries-ltd) SUDARSHAN · turning · Evidence leans up · 85% evidence 58.7 out of 100 Growth Capital Valuation Relative
13. [Singer India Ltd](https://www.sectoralpha.in/stocks/singer-india-ltd) SINGERIND · Evidence leans up · 61% evidence 58.0 out of 100 Growth Capital Valuation Relative
14. [Euro Pratik Sales Ltd](https://www.sectoralpha.in/stocks/euro-pratik-sales-ltd) EUROPRATIK · quiet · Evidence leans up · 64% evidence 57.5 out of 100 Growth Capital Valuation Relative
15. [Pramara Promotions Ltd](https://www.sectoralpha.in/stocks/pramara-promotions-ltd) PRAMARA · Too little evidence to rank firmly · 52% evidence 54.6 out of 100 Growth Capital Valuation Relative
16. [State Trading Corporation of India Ltd](https://www.sectoralpha.in/stocks/state-trading-corporation-of-india-ltd) STCINDIA · quiet · Too little evidence to rank firmly · 57% evidence 53.4 out of 100 Growth Capital Valuation Relative
17. [Patel Retail Ltd](https://www.sectoralpha.in/stocks/patel-retail-ltd) PATELRMART · turning · Evidence leans up · 64% evidence 53.2 out of 100 Growth Capital Valuation Relative
18. [Yogi Ltd](https://www.sectoralpha.in/stocks/yogi-ltd) YOGI · quiet · Evidence leans up · 64% evidence 51.2 out of 100 Growth Capital Valuation Relative
19. [Transchem Ltd](https://www.sectoralpha.in/stocks/transchem-ltd) TRANSCHEM · Too little evidence to rank firmly · 52% evidence 51.0 out of 100 Growth Capital Valuation Relative
20. [Prostarm Info Systems Ltd](https://www.sectoralpha.in/stocks/prostarm-info-systems-ltd) PROSTARM · breaking out · Evidence leans up · 64% evidence 50.8 out of 100 Growth Capital Valuation Relative
21. [Dhunseri Ventures Ltd](https://www.sectoralpha.in/stocks/dhunseri-ventures-ltd) DVL · breaking out · Evidence leans up · 78% evidence 50.6 out of 100 Growth Capital Valuation Relative
22. Bizotic Commercial Ltd losing its lead · Evidence leans up · 63% evidence 50.5 out of 100 Growth Capital Valuation Relative
23. BMW Ventures Ltd BMW · Too little evidence to rank firmly · 51% evidence 50.2 out of 100 Growth Capital Valuation Relative
24. [Cropster Agro Ltd](https://www.sectoralpha.in/stocks/cropster-agro-ltd) quiet · Evidence leans down · 65% evidence 49.1 out of 100 Growth Capital Valuation Relative
25. [MMTC Ltd](https://www.sectoralpha.in/stocks/mmtc-ltd) MMTC · quiet · Evidence leans down · 92% evidence 47.2 out of 100 Growth Capital Valuation Relative
26. [Shiv Aum Steels Ltd](https://www.sectoralpha.in/stocks/shiv-aum-steels-ltd) SHIVAUM · breaking out · Evidence leans down · 63% evidence 46.8 out of 100 Growth Capital Valuation Relative
27. [Blue Pearl Agriventures Ltd](https://www.sectoralpha.in/stocks/blue-pearl-agriventures-ltd) BPAGRI · Too little evidence to rank firmly · 51% evidence 43.8 out of 100 Growth Capital Valuation Relative
28. [Lloyds Enterprises Ltd](https://www.sectoralpha.in/stocks/lloyds-enterprises-ltd) LLOYDSENT · quiet · Evidence leans down · 71% evidence 43.1 out of 100 Growth Capital Valuation Relative
29. [Hexa Tradex Ltd](https://www.sectoralpha.in/stocks/hexa-tradex-ltd) HEXATRADEX · breaking out · Evidence leans down · 64% evidence 39.9 out of 100 Growth Capital Valuation Relative
30. [Shanti Overseas (India) Ltd](https://www.sectoralpha.in/stocks/shanti-overseas-indialtd) SHANTI · Evidence leans down · 61% evidence 39.3 out of 100 Growth Capital Valuation Relative
31. Riddhi Siddhi Gluco Biols Ltd this page turning · Evidence leans down · 83% evidence 38.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.1/35 · Revenue -38% · Profit 38.4% · Operating margin change -2.8 points · 83% evidence Capital efficiency 6.4/25 · ROCE 2.7% · Operating margin -3% · 95% evidence Valuation 6.3/20 · P/E 34.8× · PEG n/a · 50% evidence Relative strength 13.1/20 · Lead over its industry 6.2% · Lead over NIFTY 500 17% · 1 year 26.8% · 100% evidence · 5 of 12 weeks ahead Exact sum: 13.1 + 6.4 + 6.3 + 13.1 = 38.9 · What this means: Relative strength against the index is 17%, and revenue and profit growth are weak. 32. [Hardwyn India Ltd](https://www.sectoralpha.in/stocks/hardwyn-india-ltd) HARDWYN · basing · Evidence leans down · 86% evidence 38.8 out of 100 Growth Capital Valuation Relative
33. [Adani Enterprises Ltd](https://www.sectoralpha.in/stocks/adani-enterprises-ltd) ADANIENT · quiet · Evidence leans down · 93% evidence 38.1 out of 100 Growth Capital Valuation Relative
34. [PTC India Ltd](https://www.sectoralpha.in/stocks/ptc-india-ltd) PTC · quiet · Evidence leans down · 78% evidence 37.4 out of 100 Growth Capital Valuation Relative
35. [Le Merite Exports Ltd](https://www.sectoralpha.in/stocks/le-merite-exports-ltd) LEMERITE · Too little evidence to rank firmly · 59% evidence 36.8 out of 100 Growth Capital Valuation Relative
36. [Fabtech Technologies Ltd](https://www.sectoralpha.in/stocks/fabtech-technologies-ltd) FABTECH · quiet · Evidence leans down · 68% evidence 36.7 out of 100 Growth Capital Valuation Relative
37. [Uniphos Enterprises Ltd](https://www.sectoralpha.in/stocks/uniphos-enterprises-ltd) UNIENTER · turning · Too little evidence to rank firmly · 59% evidence 35.7 out of 100 Growth Capital Valuation Relative
38. Manbro Industries Ltd Too little evidence to rank firmly · 57% evidence 35.3 out of 100 Growth Capital Valuation Relative
39. Shah Foods Ltd quiet · Too little evidence to rank firmly · 53% evidence 35.3 out of 100 Growth Capital Valuation Relative
40. [BN Agrochem Ltd](https://www.sectoralpha.in/stocks/bn-agrochem-ltd) BNAGROCHEM · quiet · Most evidence points down · 64% evidence 34.1 out of 100 Growth Capital Valuation Relative
41. [Neueon Corporation Ltd](https://www.sectoralpha.in/stocks/neueon-corporation-ltd) NEUEON · quiet · Too little evidence to rank firmly · 56% evidence 33.3 out of 100 Growth Capital Valuation Relative
42. [Kothari Industrial Corporation Ltd](https://www.sectoralpha.in/stocks/kothari-industrial-corporation-ltd) KOTIC · quiet · Too little evidence to rank firmly · 53% evidence 32.9 out of 100 Growth Capital Valuation Relative
43. [Oswal Agro Mills Ltd](https://www.sectoralpha.in/stocks/oswal-agro-mills-ltd) OSWALAGRO · Too little evidence to rank firmly · 52% evidence 28.6 out of 100 Growth Capital Valuation Relative
44. [Susan Electricals India Ltd](https://www.sectoralpha.in/stocks/susan-electricals-india-ltd) quiet · Too little evidence to rank firmly · 36% evidence 61.2 out of 100 Growth Capital Valuation Relative
45. [Magnus Steel & Infra Ltd](https://www.sectoralpha.in/stocks/magnus-steel-infra-ltd) Too little evidence to rank firmly · 40% evidence 61.1 out of 100 Growth Capital Valuation Relative
46. [Vision Infra Equipment Solutions Ltd](https://www.sectoralpha.in/stocks/vision-infra-equipment-solutions-ltd) VIESL · breaking out · Too little evidence to rank firmly · 47% evidence 58.5 out of 100 Growth Capital Valuation Relative
47. [Q-Line Biotech Ltd](https://www.sectoralpha.in/stocks/q-line-biotech-ltd) QLINE · losing its lead · Too little evidence to rank firmly · 21% evidence 57.8 out of 100 Growth Capital Valuation Relative
48. Aayush Art and Bullion Ltd breaking out · Too little evidence to rank firmly · 48% evidence 57.1 out of 100 Growth Capital Valuation Relative
49. [HP Telecom India Ltd](https://www.sectoralpha.in/stocks/hp-telecom-india-ltd) HPTL · Too little evidence to rank firmly · 32% evidence 57.1 out of 100 Growth Capital Valuation Relative
50. [SK Minerals & Additives Ltd](https://www.sectoralpha.in/stocks/sk-minerals-additives-ltd) quiet · Too little evidence to rank firmly · 43% evidence 55.9 out of 100 Growth Capital Valuation Relative
51. [Aptus Pharma Ltd](https://www.sectoralpha.in/stocks/aptus-pharma-ltd) Too little evidence to rank firmly · 41% evidence 55.6 out of 100 Growth Capital Valuation Relative
52. [Mardia Samyoung Capillary Tubes Company Ltd](https://www.sectoralpha.in/stocks/mardia-samyoung-capillary-tubes-company-ltd) MSCTC · Too little evidence to rank firmly · 26% evidence 55.3 out of 100 Growth Capital Valuation Relative
53. [Proventus Agrocom Ltd](https://www.sectoralpha.in/stocks/proventus-agrocom-ltd) PROV · breaking out · Too little evidence to rank firmly · 39% evidence 54.1 out of 100 Growth Capital Valuation Relative
54. [Pervasive Commodities Ltd](https://www.sectoralpha.in/stocks/pervasive-commodities-ltd) breaking out · Too little evidence to rank firmly · 48% evidence 51.8 out of 100 Growth Capital Valuation Relative
55. [Monika Alcobev Ltd](https://www.sectoralpha.in/stocks/monika-alcobev-ltd) MONIKA · Too little evidence to rank firmly · 27% evidence 49.9 out of 100 Growth Capital Valuation Relative
56. [Onix Solar Energy Ltd](https://www.sectoralpha.in/stocks/onix-solar-energy-ltd) ONIXSOLAR · quiet · Too little evidence to rank firmly · 47% evidence 45.8 out of 100 Growth Capital Valuation Relative
57. Arvaya Healthcare Ltd ARVAYA · quiet · Too little evidence to rank firmly · 46% evidence 45.4 out of 100 Growth Capital Valuation Relative
58. [A-1 Ltd](https://www.sectoralpha.in/stocks/a-1-ltd) A1L · Too little evidence to rank firmly · 33% evidence 45.3 out of 100 Growth Capital Valuation Relative
59. [Satani Bearings Ltd](https://www.sectoralpha.in/stocks/satani-bearings-ltd) breaking out · Too little evidence to rank firmly · 42% evidence 42.9 out of 100 Growth Capital Valuation Relative
60. [Keto Motors Ltd](https://www.sectoralpha.in/stocks/keto-motors-ltd) quiet · Too little evidence to rank firmly · 42% evidence 40.9 out of 100 Growth Capital Valuation Relative
61. [Aerpace Industries Ltd](https://www.sectoralpha.in/stocks/aerpace-industries-ltd) breaking out · Too little evidence to rank firmly · 36% evidence 37.9 out of 100 Growth Capital Valuation Relative
62. [Prabhatam Infra Venture Ltd](https://www.sectoralpha.in/stocks/prabhatam-infra-venture-ltd) PRABHATAM · Too little evidence to rank firmly · 22% evidence 36.8 out of 100 Growth Capital Valuation Relative
63. [RRP Semiconductor Ltd](https://www.sectoralpha.in/stocks/rrp-semiconductor-ltd) RRP · Too little evidence to rank firmly · 42% evidence 34.0 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Trading](https://www.sectoralpha.in/sectors/trading), all 63 compared on one page. ## Which companies are close to Riddhi Siddhi Gluco Biols in size? Riddhi Siddhi Gluco Biols is the 48th largest of 59 Trading companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: DC Infotech & Communication, Blue Pearl Agriventures and Transchem. Just below it: Singer India, SK Minerals & Additives and Bhatia Communications & Retail (India). ### Trading companies close in size

1. [DC Infotech & Communication Ltd](https://www.sectoralpha.in/stocks/dc-infotech-communication-ltd) ₹541 crore
2. [Blue Pearl Agriventures Ltd](https://www.sectoralpha.in/stocks/blue-pearl-agriventures-ltd) ₹539 crore
3. [Transchem Ltd](https://www.sectoralpha.in/stocks/transchem-ltd) ₹499 crore
4. Riddhi Siddhi Gluco Biols Ltd ₹492 crore
5. [Singer India Ltd](https://www.sectoralpha.in/stocks/singer-india-ltd) ₹483 crore
6. [SK Minerals & Additives Ltd](https://www.sectoralpha.in/stocks/sk-minerals-additives-ltd) ₹479 crore
7. [Bhatia Communications & Retail (India) Ltd](https://www.sectoralpha.in/stocks/bhatia-communications-retail-indialtd) ₹456 crore

[All 59 Trading companies, largest first](https://www.sectoralpha.in/sectors/trading#all-companies)

### Companies close in size in other industries

1. [HRS Aluglaze Ltd](https://www.sectoralpha.in/stocks/hrs-aluglaze-ltd) ₹492 crore · Construction - Civil/Turnkey
2. [International Conveyors Ltd](https://www.sectoralpha.in/stocks/international-conveyors-ltd) ₹492 crore
3. Riddhi Siddhi Gluco Biols Ltd ₹492 crore
4. [Black Rose Industries Ltd](https://www.sectoralpha.in/stocks/black-rose-industries-ltd) ₹491 crore · Speciality Chemicals
5. [Connplex Cinemas Ltd](https://www.sectoralpha.in/stocks/connplex-cinemas-ltd) ₹490 crore · Entertainment - Content Providers

## What else do people ask about Riddhi Siddhi Gluco Biols? ### What is Riddhi Siddhi Gluco Biols's share price today? Riddhi Siddhi Gluco Biols Ltd's share price is ₹665.05, +22.3% over the past year. The whole company is worth ₹474 Cr on the market. In the last 52 weeks it traded between ₹411 to ₹823; today it is 62% of the way up from the low, 1.0% below its 200-day average (as of 3 November 2026). ### What were Riddhi Siddhi Gluco Biols's latest quarterly results? Riddhi Siddhi Gluco Biols Ltd reported revenue of ₹89.9 Cr and net profit of ₹3.0 Cr for the Jun 2026 quarter. Revenue fell 41.9% and profit fell 62.6% compared with a year earlier. Earnings per share were ₹4.29 (as of 3 November 2026). ### What is Riddhi Siddhi Gluco Biols's market cap? Riddhi Siddhi Gluco Biols Ltd's market capitalisation is ₹474 Cr at a share price of ₹665.05. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Riddhi Siddhi Gluco Biols performing? Riddhi Siddhi Gluco Biols Ltd's share price has been rising for 25 weeks. In its latest quarter, revenue fell 41.9% and profit fell 62.6% compared with a year earlier. Over the past 13 weeks it has done worse than the NIFTY 500, for 1 week running (as of 3 November 2026). ### Will Riddhi Siddhi Gluco Biols's share price go up? This page does not forecast Riddhi Siddhi Gluco Biols Ltd's share price. What it shows instead: the share price is ₹665.05, and it has been rising for 25 weeks. Its P/E of 33.5× is higher than 97% of its own last 10 years (as of 3 November 2026). ### Where is Riddhi Siddhi Gluco Biols in its business cycle? Riddhi Siddhi Gluco Biols Ltd's FY26 operating margin was −5.0%, against a 11-year range of −9.0% to 13.0%: the low end of its own range, which is often where recoveries start. The latest quarter was −3.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Riddhi Siddhi Gluco Biols story? The main question: foreign institutions moved +2.7 percentage points over 8 quarters while the business went the other way. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Riddhi Siddhi Gluco Biols a stock worth studying right now? What the numbers show: Riddhi Siddhi Gluco Biols Ltd's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: whether the owners’ moves turn back in line with the business. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.